Four clients to present data at upcoming Society for Biological Sciences meeting

Woburn, MA, September 12, 2006 - BioTrove, Inc. announced today the successful screening of more than two million individual samples using their RapidFire™ Lead Discovery System. RapidFire™ is a unique, mass spectrometry-based, high-throughput screening platform that facilitates label-free screening of challenging drug targets using native substrates.

BioTrove currently provides screening services and instrumentation to nine, large pharmaceutical and biotechnology companies. Four of these clients will present results of lead discovery campaigns at the upcoming Society for Biomolecular Sciences (SBS) conference (Seattle, WA, September 17-21), demonstrating RapidFire™ screening of previously intractable drug targets.

RapidFire™ Lead Discovery uses mass spectrometry to enable high throughput screening of functional biochemical assays via label-free analysis of native substrates. The unique platform can analyze individual assays at throughputs of four to eight seconds per sample — a dramatic increase in throughput over conventional liquid chromatography-mass spectrometry systems.

BioTrove offers access to the Lead Discovery System as a screening service that includes assay development, primary screening, and support of secondary screening and chemistry programs. Technology transfer is available for clients who prefer to own their systems.

"We feel that the addition of six new customers in the past year, along with the screening of our two millionth client sample, truly validates the ability of the RapidFire™ platform to unlock the potential of a wide range of challenging HTS targets," said Can (Jon) Özbal, Ph.D., Director of the RapidFire™ program. "The RapidFire™ system has now been used to identify lead compounds in a wide range of high-throughput screening projects, ranging from key metabolic disease, cardiovascular, and oncology targets to novel targets in the anti-infective and anti-fungal areas."

Presentations will be made at the upcoming SBS meeting by BioTrove's RapidFire™ clients from Bayer Pharmaceuticals, Pfizer Inc., Schering Plough Research Institute, and Sirtris Pharmaceuticals. BioTrove will also exhibit at SBS, booth number 636.

About BioTrove, Inc.

BioTrove offers two innovative platform technologies that dramatically increase the throughput of pharmaceutical screening and SNP genotyping.

RapidFire™ Lead Discovery enables difficult targets (lipids, fatty acids, phospholipids, steroids, prostaglandins, and others) to be screened using a high-throughput, native detection method (high throughput mass spectrometry) in less than 8 seconds per sample.

OpenArray™ enables genomics researchers to generate up to hundreds of thousands of SNP data points per day. The flexible format and nanoliter scale of the OpenArray™ system allows adjustment of sample and assay numbers, for economical high-throughput genotyping.

For more information, please visit www.biotrove.com or contact:

Selena Larkin, Ph.D.
BioTrove, Inc.
571 451 4389
slarkin@biotrove.com

Courtney Harris
Feinstein Kean Healthcare
617-761-6744
courtney.harris@fkhealth.com